title: Dynamic changes of the inflammation-based index predict mortality following chemoembolisation for hepatocellular carcinoma: a prospective study.
abstract: BACKGROUND
  Transarterial chemoembolisation (TACE) is a standard treatment for unresectable, intermediate stage hepatocellular carcinoma (HCC). Survival after TACE, however, can be highly variable, with no suitable biomarker predicting therapeutic outcome. The inflammation-based index (IBI) has previously been shown to independently predict overall survival (OS) in all stages of HCC.
  
  
  OBJECTIVE
  To explore the prognostic ability of IBI as a predictor of survival after TACE.
  
  
  METHODS
  Baseline staging, biochemical and clinicopathological features including IBI were studied in a derivation set of 64 patients undergoing TACE for intermediate stage HCC. Dynamic changes in IBI before and after TACE were studied as predictors of survival using both a univariate and multivariate Cox regression model and further validated in two independent patient cohorts from Korea (n = 76) and Japan (n = 577).
  
  
  RESULTS
  Pre-treatment IBI predicted for OS in the derivation set (P = 0.001). Other univariate predictors of OS included radiological response to TACE (P < 0.001), pre-TACE CLIP score (P < 0.01), tumour diameter >5 cm (P = 0.05) and AFP ≥400 (P < 0.001). Normalisation of IBI post-TACE was associated with radiological response by mRECIST criteria and improved OS (P < 0.001). Normalisation of IBI remained a significant multivariate predictor of OS in both the derivation and validation sets (P < 0.001).
  
  
  CONCLUSIONS
  Normalisation of IBI after TACE is shown to be an independent predictor of survival and may be integrated into the retreatment criteria for repeat TACE in intermediate stage HCC. IBI and its dynamic changes after treatment are validated as a biomarker allowing the stratification of patients with a significant survival advantage following initial TACE.
authors.affiliation: Division of Experimental Medicine, Imperial College London, Hammersmith Hospital, London, UK.
authors.forename: D J
authors.initials: DJ
authors.lastname: Pinato
authors.forename: G
authors.initials: G
authors.lastname: Karamanakos
authors.forename: T
authors.initials: T
authors.lastname: Arizumi
authors.forename: D
authors.initials: D
authors.lastname: Adjogatse
authors.forename: Y W
authors.initials: YW
authors.lastname: Kim
authors.forename: J
authors.initials: J
authors.lastname: Stebbing
authors.forename: M
authors.initials: M
authors.lastname: Kudo
authors.forename: J W
authors.initials: JW
authors.lastname: Jang
authors.forename: R
authors.initials: R
authors.lastname: Sharma
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015415:Biomarkers / Q000032:analysis; D006528:Carcinoma, Hepatocellular / Q000150:complications / Q000401:mortality* / Q000473:pathology / Q000628:therapy*; D016461:Chemoembolization, Therapeutic; D005260:Female; D006801:Humans; D007249:Inflammation / Q000150:complications / Q000175:diagnosis* / Q000401:mortality; D007564:Japan; D008113:Liver Neoplasms / Q000150:complications / Q000401:mortality* / Q000473:pathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D011237:Predictive Value of Tests; D011379:Prognosis; D016016:Proportional Hazards Models; D011446:Prospective Studies; D056910:Republic of Korea; D012189:Retrospective Studies; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D015415:Biomarkers